Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
74 participants
INTERVENTIONAL
2022-01-17
2023-07-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Performance and Safety of a Medical Device Developed to Improve the Reading of Dyslexic Patients
NCT04157829
Dyslexics' Visual Attention Field
NCT03285789
Assessment of Visual Dyslexia Remediation Protocols - Dyslexia REMEDIATION
NCT05514457
Study of Visual-spatial Attention by Eye Tracking as a Function of Central or Peripheral Visual Impairment
NCT03505398
V5/MT Stimulation on Reading and Reading-related Measures in Developmental Dyslexia
NCT05972200
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study 150 children with dyslexia will be randomized in tow groups. On the first group children will be trained first with MAEVAD then with a control training that does not stimulate the VA span. On contrary, on the second group children will first perform the control training and then MAEVAD.
For each intervention the sessions will lasts 15 minutes. 5 sessions are planned per weeks for 6 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
For each intervention the sessions will lasts 15 minutes. 5 sessions are planned per weeks for 6 weeks.
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MAEVAD - DeCaLigne
The experimental group will first receive MAEVAD then the control therapy
MAEVAD
MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into "le Royaume d'Adelia", a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character.
DeCaLigne - MAEVAD
The control group will first receive the control therapy then MAEVAD
DeCaLigne
DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the "royaume d'Adelia" in order to control the motivational effect of the serious game.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MAEVAD
MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into "le Royaume d'Adelia", a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character.
DeCaLigne
DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the "royaume d'Adelia" in order to control the motivational effect of the serious game.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Dyslexic children with a VA span deficit (composite visual-attention span below the fifteenth percentile and a letter threshold above or equal to the twentieth percentile with the - - - Evadys(c) battery)
* Established diagnosis of Dyslexia
* Children whose parents/legal guardians have signed informed consent and agree to participate in the study
* Children whose first language is French or who have been educated in French since kindergarten
* Raven's Progressive Matrices score above the 20th percentile or a WISC IV or V Verbal Comprehension Index or WISC IV or V Perceptual/Fluid Reasoning Index above 85 or documented/objectifiable absence of intellectual deficit
* Child with access to a computer
* Normal or corrected vision and audition
Exclusion Criteria
* Neurological disorders
* Children who have missed 3 months or more of school in the current or previous year (excluding lockdown)
* Children not affiliated to a social security scheme
8 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Humans Matter
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mélodie FOUILLEN, PhD
Role: STUDY_CHAIR
Humans Matter
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MARTINELLI Karen
Ajaccio, , France
BERARD Marine
Albertville, , France
CARCEY-CADET Elise
Albertville, , France
KOUASSI-PUJOL Marie
Albi, , France
CLAVIER-MARCOUX Laetitia
Antibes, , France
BOCCOGNANI Jordane
Argences en Aubrac, , France
CHAUVET Clémence
Arles, , France
CHABERT Claire
Bagnères-de-Bigorre, , France
SCHMITT Véronique
Biganos, , France
CRABÉ Marion
Billère, , France
BIRAN Sandrine
Bordes, , France
VALLERY Théoline
Brest, , France
LADOUL Marine
Brive-la-Gaillarde, , France
COURANT Sabrina
Cabasse, , France
CONTESTI Véronique
Champagne-au-Mont-d'Or, , France
MINIAC-FOURNIER Stéphanie
Château-Gontier, , France
CASTERES Catherine
Digoin, , France
PASQUIER Amélie
Fay-de-Bretagne, , France
LEGENDRE Laure
Fontenay-sous-Bois, , France
FORTIER Anne
Garches, , France
BLANC Emilie
Givors, , France
KRAYEM Mona
Guichainville, , France
RIZK Joumana
Guichainville, , France
SHAW PERRIN Anne-Sophie
Irigny, , France
DE MUYNCK Solène
Lamballe, , France
CADALEN Hélène
Lanmeur, , France
VOLUET FROMENT Adeline
Le Chesnay, , France
BERNARD-DENIS Fabienne
Le Havre, , France
TERRASSON Cécile
Le Touquet-Paris-Plage, , France
CALAIS Cécile
Liancourt, , France
Britt
Lux, , France
GOBÉ Valérie
Machecoul, , France
JORDANIS Mélanie
Marignier, , France
VERLOT-MORY Ludivine
Meuilley, , France
MAZERAN Anne-Cécile
Miribel, , France
KIS Nathalie
Montigny-le-Bretonneux, , France
EMERIAU Mathilde
Nantes, , France
LHUILLIER Françoise
Neufchâteau, , France
LEJOSNE Julie
Paimpol, , France
BRESSON Raphaëlle
Plaisir, , France
BERTHELOT Florence
Plérin, , France
BERTHOLOM Anne-Marine
Ploudalmézeau, , France
ZIMMERMAN Amélie
Remoulins, , France
CAMUS-BRUNEAU Anne
Rezé, , France
KOCHEL Jeanne-Marie
Saint-Germain-en-Laye, , France
VIERLING Pauline
Saint-Leu, , France
LECLERC LE COADOU Rozenn
Saint-Lô, , France
NADAUD Stéphanie
Saint-Nom-la-Bretêche, , France
REVERSE Christelle
Saint-Péray, , France
DESCENDRE Myriam
Saint-Quentin, , France
RAYNAUD LEGROS Caroline
Sainte-Anne, , France
AÏT LEMKADEM Mimouna
Sartrouville, , France
FRITSCH Colombine
Schiltigheim, , France
CARRIQUE Pascale
Tourrettes, , France
KALCK Christine
Vendenheim, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A01457-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.